Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John S Markowitz

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Clinical Therapeutics|March 19, 2013
Transforming events: hepatic metabolism and individual variabilityJohn S Markowitz
Clinical Therapeutics|March 3, 2015
CNS drugs: the needs are great, the advances, incrementalJohn S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 28, 2020
Natural Products as Modulators of CES1 ActivityYuli Qian, John S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 5, 2022
Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic ModelsYuli Qian, John S Markowitz
Planta Medica|January 25, 2017
An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis)Ahmed A Albassam, John S Markowitz
European Journal of Clinical Pharmacology|August 1, 2012
Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activationHao-Jie Zhu, John S Markowitz
Journal of Child and Adolescent Psychopharmacology|September 15, 2017
The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity DisorderJohn S Markowitz, Kennerly S Patrick
Psychopharmacology Bulletin|October 26, 2002
Psychoactive drug interactions with pharmacotherapy for diabetesC Lindsay DeVane, John S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 22, 2008
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variantsHao-Jie Zhu, John S Markowitz
Expert Opinion on Drug Metabolism & Toxicology|July 15, 2014
A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorderJohn S Markowitz, Bryan J Brinda
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Clinical Therapeutics|March 19, 2013
Transforming events: hepatic metabolism and individual variabilityJohn S Markowitz
Clinical Therapeutics|March 3, 2015
CNS drugs: the needs are great, the advances, incrementalJohn S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 28, 2020
Natural Products as Modulators of CES1 ActivityYuli Qian, John S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 5, 2022
Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic ModelsYuli Qian, John S Markowitz
Planta Medica|January 25, 2017
An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis)Ahmed A Albassam, John S Markowitz
European Journal of Clinical Pharmacology|August 1, 2012
Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activationHao-Jie Zhu, John S Markowitz
Journal of Child and Adolescent Psychopharmacology|September 15, 2017
The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity DisorderJohn S Markowitz, Kennerly S Patrick
Psychopharmacology Bulletin|October 26, 2002
Psychoactive drug interactions with pharmacotherapy for diabetesC Lindsay DeVane, John S Markowitz
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 22, 2008
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variantsHao-Jie Zhu, John S Markowitz
Expert Opinion on Drug Metabolism & Toxicology|July 15, 2014
A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorderJohn S Markowitz, Bryan J Brinda
Pageof 12